Continuous opioid therapy (COT) is rarely advisable for refractory chronic daily headache: Limited efficacy, risks, and proposed guidelines

Headache

Volumn 48, Issue 6, 2008, Pages 838-849

  Saper, Joel R ^a   Lake III, Alvin E ^a  

^a Michigan Head Pain and Neurological Institute   (United States)

Author keywords

Chronic daily headache; Guidelines; Opioids; Refractory headache

Indexed keywords

METHADONE; OPIATE; PLACEBO;

AGE DISTRIBUTION; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FIBROMYALGIA; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERALGESIA; LONG TERM CARE; MEDICATION ERROR; NAUSEA; NEUROPATHIC PAIN; PAIN; PATIENT ATTITUDE; PATIENT CARE; PATIENT MONITORING; PATIENT SAFETY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; REVIEW; SEXUAL HORMONE IMBALANCE; SIDE EFFECT; SUDDEN DEATH; TREATMENT FAILURE; VOMITING;

ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; GUIDELINES AS TOPIC; HEADACHE DISORDERS; HUMANS; PAIN, INTRACTABLE; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 44849094515     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2008.01153.x     Document Type: Review

References (78)

1. Rothrock JF. Lagniappe. Headache. 2007 47 : 1232 1233.
2. Rothrock JF. Management of chronic daily headache utilizing a uniform treatment pathway. Headache. 1999 39 : 650 653.
3. Potter M, Schafer S, Gonzalez-Mendez E, et al. Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco. J Fam Pract. 2001 50 : 145 151.
4. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: A systematic review. J Pain Symptom Manage. 2003 26 : 1026 1048.
5. Lanser P, Gesell S. Pain management: The fifth vital sign. Health Benchmarks. 2001 8 : 68 70.
6. Mularski RA, White-Chu F, Overbay D, Miller L, Asch SM, Ganzini L. Measuring pain as the 5th vital sign does not improve quality of pain management. J Gen Intern Med. 2006 21 : 607 612.
7. Lucas CE, Vlahos AL, Ledgerwood AM. Kindness kills: The negative impact of pain as the fifth vital sign. J Am Coll Surg. 2007 205 : 101 107.
8. Saper JR, Lake AE 3rd. Sustained opioid therapy should rarely be administered to headache patients: Clinical observations, literature review, and proposed guidelines. Headache Curr. 2006 3 : 67 70.
9. Schulman EA, Lake AE 3rd., Goadsby PJ, et al. Defining refractory migraine (RM) and refractory chronic migraine (RCM): Proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008 48 : 778 782.
10. Saper JR, Lake AE 3rd., Hamel RL, Lutz TE, Branca B, Sims D. Long-term scheduled opioid treatment for intractable headache: 3-year outcome report. Headache. 2000 20 : 380 (Abstract).
11. Saper JR, Hamel RL, Lake AE 3rd., Lutz TE, Sims D, Branca B. Structured opioid maintenance therapy for refractory chronic headache. Headache. 1997 37 : 329 (Abstract).
12. Saper JR, Hamel RL, Lake AE 3rd., Lutz TE, Branca B, Sims D. Long-term scheduled opioid treatment for refractory headache: Second interim outcome report. Headache. 1998 38 : 401 402 (Abstract).
13. Saper JR, Lake AE 3rd., Hamel RL, Lutz TE, Branca B, Sims D. Long-term scheduled opioid treatment for intractable headache: Third year outcome of a five year study. Headache. 1999 39 : 380 (Abstract).
14. Rothrock J. Methadone therapy in refractory chronic migraine. Headache. 2005 45 : 830 (Abstract).
15. Saper JR, Lake AE 3rd., Hamel RL, et al. Daily scheduled opioids for intractable head pain: Long-term observations of a treatment program. Neurology. 2004 62 : 1687 1694.
16. Jerome A, Gross RT. Pain disability index: Construct and discriminant validity. Arch Phys Med Rehabil. 1991 72 : 920 922.
17. Tait RC, Pollard CA, Margolis RB, Duckro PN, Krause SJ. The pain disability index: Psychometric and validity data. Arch Phys Med Rehabil. 1987 68 : 438 441.
18. Tait RC, Chibnall JT, Krause S. The pain disability index: Psychometric properties. Pain. 1990 40 : 171 182.
19. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. CMAJ. 2006 174 : 1589 1594.
20. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain. 2004 112 : 372 380.
21. Breivik H. Opioids in chronic non-cancer pain, indications and controversies. Eur J Pain. 2005 9 : 127 130.
22. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage. 2008 35 : 214 228.
23. Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: An epidemiological study. Pain. 2006 125 : 172 179.
24. Buntin-Mushock C, Phillip L, Moriyama K, Palmer PP. Age-dependent opioid escalation in chronic pain patients. Anesth Analg. 2005 100 : 1740 1745.
25. Wang Y, Mitchell J, Moriyama K, et al. Age-dependent morphine tolerance development in the rat. Anesth Analg. 2005 100 : 1733 1739.
26. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: Effect of age, gender, and race. Clin Pharmacol Ther. 2003 74 : 102 112.
27. Cowan DT, Wilson-Barnett J, Griffiths P, Allan LG. A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Med. 2003 4 : 340 351.
28. Capobianco DJ, Swanson JW, Dodick DW. Medication-induced (analgesic rebound) headache: Historical aspects and initial descriptions of the North American experience. Headache. 2001 41 : 500 502. May
29. Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: Clinical implications. Headache. 2006 46 (Suppl. 4 S202 S211.
30. Zwart JA, Dyb G, Hagen K, Svebak S, Holmen J. Analgesic use: A predictor of chronic pain and medication overuse headache: The Head-HUNT Study. Neurology. 2003 61 : 160 164.
31. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001 41 : 303 309.
32. Katsarava Z, Jensen R. Medication-overuse headache: Where are we now? Curr Opin Neurol. 2007 20 : 326 330.
33. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006 46 : 1334 1343.
34. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006 26 : 742 746.
35. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: Recovery of therapeutic responsiveness. Cephalalgia. 2006 26 : 1192 1198.
36. Warner JS. The outcome of treating patients with suspected rebound headache. Headache. 2001 41 : 685 692.
37. Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V. Medication overuse headache: Rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005 25 : 12 15.
38. Grazzi L, Andrasik F, D'Amico D, et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: Outcome at 3 years. Headache. 2002 42 : 483 490.
39. Grazzi L, Andrasik F. Medication-overuse headache: Description, treatment, and relapse prevention. Curr Pain Headache Rep. 2006 10 : 71 77.
40. Angst MS, Clark JD. Opioid-induced hyperalgesia: A qualitative systematic review. Anesthesiology. 2006 104 : 570 587.
41. Ossipov MH. Opioids in the treatment of headache: Perspective from the Bench. Headache Curr. 2006 3 : 53 62.
42. Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep. 2006 10 : 67 70.
43. Celerier E, Gonzalez JR, Maldonado R, Cabanero D, Puig MM. Opioid-induced hyperalgesia in a murine model of postoperative pain: Role of nitric oxide generated from the inducible nitric oxide synthase. Anesthesiology. 2006 104 : 546 555.
44. Liang DY, Liao G, Wang J, et al. A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology. 2006 104 : 1054 1062.
45. Trang T, Quirion R, Jhamandas K. The spinal basis of opioid tolerance and physical dependence: Involvement of calcitonin gene-related peptide, substance P, and arachidonic acid-derived metabolites. Peptides. 2005 26 : 1346 1355.
46. Trang T, Sutak M, Jhamandas K. Involvement of cannabinoid (CB1)-receptors in the development and maintenance of opioid tolerance. Neuroscience. 2007 146 : 1275 1288.
47. King T, Gardell LR, Wang R, et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain. 2005 116 : 276 288.
48. Vera-Portocarrero LP, Zhang ET, King T, et al. NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways. Pain. 2007 129 : 35 45.
49. Simonin F, Schmitt M, Laulin JP, et al. RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci USA. 2006 103 : 466 471.
50. Ossipov MH, Lai J, King T, et al. Antinociceptive and nociceptive actions of opioids. J Neurobiol. 2004 61 : 126 148.
51. Xie JY, Herman DS, Stiller CO, et al. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci. 2005 25 : 409 416.
52. Watkins LR, Hutchinson R, Johnston IN, Mauer SF. Glial novel counter-regulators of opioid analgesia. Trends Neurosci. 2005 12 : 661 669.
53. Hutchinson MR, Bland ST, Johnson KW, et al. Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence, and reward. Scientific World Journal. 2007 7 : 98 111.
54. Watkins LR, Milligan ED, Maier SF. Glial activation: A driving force for pathological pain. Trends Neurosci. 2001 24 : 450 455.
55. Tegeder I, Geisslinger G. Opioids as modulators of cell death and survival - unraveling mechanisms and revealing new indications. Pharmacol Rev. 2004 56 : 351 369.
56. Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005 45 : 850 861.
57. Manchikanti L, Pampati V, Damron KS, Fellows B, Barnhill RC, Beyer CD. Prevalence of opioid abuse in interventional pain medicine practice settings: A randomized clinical evaluation. Pain Physician. 2001 4 : 358 365.
58. Manchikanti L, Damron KS, McManus CD, Barnhill RC. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: A prospective, observational study. Pain Physician. 2004 7 : 431 437.
59. Manchikanti L, Giordano J, Boswell MV, Fellows B, Manchukonda R, Pampati V. Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients. J Opioid Manag. 2007 3 : 89 100.
60. Edlund MJ, Steffick D, Hudson T, Harris KM, Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain. 2007 129 : 355 362.
61. Food and Drug Administration, Department of Public Health and Human Services. Death, narcotic overdose, and serious cardiac arrhythmias: Information for healthcare professionals on methadone. J Pain Palliat Care Pharmacother. 2007 21 : 69 71.
62. Wolff K. Characterization of methadone overdose: Clinical considerations and the scientific evidence. Ther Drug Monit. 2002 24 : 457 470.
63. Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med. 2008 121 : 66 71.
64. Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: Evidence for opioid-induced inhibition of adrenal androgen production. J Pain. 2006 7 : 901 907.
65. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008 9 : 28 36.
66. Hammer RP Jr., Ricalde AA, Seatriz JV. Effects of opiates on brain development. Neurotoxicology. 1989 10 : 475 483.
67. Bunikowski R, Grimmer I, Heiser A, Metze B, Schafer A, Obladen M. Neurodevelopmental outcome after prenatal exposure to opiates. Eur J Pediatr. 1998 157 : 724 730.
68. Moe V. Foster-placed and adopted children exposed in utero to opiates and other substances: Prediction and outcome at four and a half years. J Dev Behav Pediatr. 2002 23 : 330 339.
69. Meares S, Shores EA, Batchelor J, et al. The relationship of psychological and cognitive factors and opioids in the development of the postconcussion syndrome in general trauma patients with mild trau matic brain injury. J Int Neuropsychol Soc. 2006 12 : 792 801.
70. Chapman SL, Byas-Smith MG, Reed BA. Effects of intermediate - and long-term use of opioids on cognition in patients with chronic pain. Clin J Pain. 2002 18 : S83 S90.
71. Preter M, Klein DF. Panic, suffocation false alarms, separation anxiety and endogenous opioids. Prog Neuropsychopharmacol Biol Psychiatry. 2007.
72. Mystakidou K, Tsilika E, Parpa E, Papageorgiou C, Georgaki S, Vlahos L. Investigating the effects of TTS-fentanyl for cancer pain on the psychological status of patients naive to strong opioids: An open label study. Cancer Nurs. 2004 27 : 127 133.
73. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC : American Psychiatric Association 2000.
74. Blakemore SJ. Development of the social brain during adolescence. Q J Exp Psychol (Colchester). 2008 61 : 40 49.
75. Horska A, Kaufmann WE, Brant LJ, Naidu S, Harris JC, Barker PB. In vivo quantitative proton MRSI study of brain development from childhood to adolescence. J Magn Reson Imaging. 2002 15 : 137 143.
76. Paus T. Mapping brain maturation and cognitive development during adolescence. Trends Cogn Sci. 2005 9 : 60 68.
77. Monteiro Caran EM, Dias CG, Seber A, Petrilli AS. Clinical aspects and treatment of pain in children and adolescents with cancer. Pediatr Blood Cancer. 2005 45 : 925 932.
78. Susman E. Cancer pain management guidelines issued for children; adult guidelines updated. J Natl Cancer Inst. 2005 97 : 711 712.